Document is current

Article History

Accepted: 23 January 2023

First Online: 15 February 2023

Declarations

:

: Open access funding provided by Università degli Studi di Verona within the CRUI-CARE Agreement.

: Gianluca Trifirò has served in the last 3 years on advisory boards/seminars funded by SANOFI, Eli Lilly, AstraZeneca, Abbvie, Servier, Mylan, Gilead, and Amgen; he was the scientific director of a Master program on pharmacovigilance, pharmacoepidemiology, and real-world evidence, which has received a non-conditional grant from various pharmaceutical companies; and he coordinated a pharmacoepidemiology team at the University of Messina until October 2020, which has received funding for conducting observational studies from various pharmaceutical companies (Boehringer Ingelheim, Daichii Sankyo, PTC Pharmaceuticals). He is also a scientific coordinator of the academic spin-off “INSPIRE srl”, which has received funding for conducting observational studies from contract research organizations (RTI Health Solutions, Pharmo Institute N.V.). None of these listed activities is related to the topic of the article. The other authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the article apart from those disclosed.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: All authors contributed equally to this work. All authors read and approved the final version.